ArticleThyroid : official journal of the American Thyroid Association2006
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
Article in Thyroid : official journal of the American Thyroid Association, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980103 (Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer), which is not on this map. Cited by 230 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
Who cites it
230 citing papers in PubMed, 11 syntheses or guidelines pooled it, 690 citations in OpenAlex.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.Thyroid : official journal of the American Thyroid Association · 2024Pooled it
- Pooled it
- Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Pooled it
- Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis.Endocrine-related cancer · 2021Pooled it
- Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2020Pooled it
- Pooled it
- External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.Head & neck · 2016Guideline
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Guideline
- SEOM clinical guidelines for the treatment of thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Guideline
- Early Side Effects of rhTSH-Aided Radioiodine Ablation and Treatment of Differentiated Thyroid Cancer: A Real-World Experience.World journal of nuclear medicine · 2026Article
- The Brazilian Transition in Differentiated Thyroid Carcinoma Management: A 25-Year Nationwide Analysis of Declining High-Activity Radioiodine Use (2000-2024).Archives of endocrinology and metabolism · 2026Article
- A Qualitative Study of Clinician Barriers and Facilitators to De-escalation of Thyroid Stimulating Hormone Suppression in Thyroid Cancer Survivors.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Comparable long-term survival outcomes after lobectomy versus total thyroidectomy treatment of minimal extrathyroidal extension differentiated thyroid cancer patients.Gland surgery · 2026Article
- TSH suppression therapy from an individualized perspective: from mechanism to clinical decision-making.Frontiers in endocrinology · 2026Review
- Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Efficacy of postoperative thyroid-stimulating hormone inhibition therapy in differentiated thyroid cancer in China: a systematic literature review and meta-analysis.Gland surgery · 2025Article
- Total Thyroidectomy vs. Lobectomy in Papillary Thyroid Microcarcinoma: A Contested Gold Standard.Journal of personalized medicine · 2025Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 11 institutions in 2 countries.
Funding
Abstract
This analysis was performed to determine the effect of initial therapy on the outcomes of thyroid cancer patients. The study setting was a prospectively followed multi-institutional registry. Patients were stratified as low risk (stages I and II) or high risk (stages III and IV). Treatments employed included near-total thyroidectomy, administration of radioactive iodine, and thyroid hormone suppression therapy. Outcome measures were overall survival, disease-specific survival, and disease-free survival. Near-total thyroidectomy, radioactive iodine, and aggressive thyroid hormone suppression therapy were each independently associated with longer overall survival in high-risk patients. Near-total thyroidectomy followed by radioactive iodine therapy, and moderate thyroid hormone suppression therapy, both predicted improved overall survival in stage II patients. No treatment modality, including lack of radioactive iodine, was associated with altered survival in stage I patients. Based on our overall survival data, we confirm that near-total thyroidectomy is indicated in high-risk patients. We also conclude that radioactive iodine therapy is beneficial for stage II, III, and IV patients. Importantly, we show for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high-risk patients, but are achieved with modest suppression in stage II patients. We were unable to show any impact, positive or negative, of specific therapies in stage I patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.